| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 05/10/2001 | WO2001032658A1 Polyazanaphthalene compound and medicinal use thereof |
| 05/10/2001 | WO2001032639A1 Nonpeptide substituted benzothiazepines as vasopressin antagonists |
| 05/10/2001 | WO2001032263A1 Use of dopamine-d3 receptor agonists for the therapy of salt-dependent hypertension |
| 05/10/2001 | WO2001032216A2 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | WO2001032167A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 05/10/2001 | WO2001032156A2 Methods for treating fibroproliferative diseases |
| 05/10/2001 | WO2001005974A3 The il-1l1 gene and polypeptide products |
| 05/10/2001 | WO2001004122A3 New 2,3-benzodiazepine derivatives |
| 05/10/2001 | WO2001000183A3 COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS |
| 05/10/2001 | WO2000073276A3 Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists |
| 05/10/2001 | WO2000063241A3 Methods and compositions for modulating an immune response |
| 05/10/2001 | US20010001104 Thienopyridine compounds, their production and use |
| 05/10/2001 | US20010001097 Stress-follower circuit configuration |
| 05/10/2001 | CA2389672A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 05/10/2001 | CA2389666A1 Production of polymorphic forms i and ii of finasteride by complexation with group i or ii metal salts |
| 05/10/2001 | CA2389661A1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | CA2389644A1 A novel polypeptide hormone phosphatonin |
| 05/10/2001 | CA2389643A1 Use of dopamine-d3 receptor agonists for the therapy of salt-dependent hypertension |
| 05/10/2001 | CA2389575A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 05/10/2001 | CA2389574A1 Ghsr ligand polypeptides and dnas thereof |
| 05/10/2001 | CA2389439A1 Nonpeptide substituted benzothiazepines as vasopressin antagonists |
| 05/10/2001 | CA2389335A1 Gene expression directed by a super-psa promoter |
| 05/10/2001 | CA2387801A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | CA2387785A1 Human transferase molecules |
| 05/10/2001 | CA2387754A1 10 human secreted proteins |
| 05/10/2001 | CA2386938A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 05/10/2001 | CA2386641A1 32 human secreted proteins |
| 05/09/2001 | EP1097150A1 Imidazolyl derivatives |
| 05/09/2001 | EP1097149A1 Bicyclohexane derivatives |
| 05/09/2001 | EP1096932A2 Antihypertensive combination of valsartan and calcium channel blocker |
| 05/09/2001 | CN1294013A Medicine for treating prostatic hyperplasia |
| 05/09/2001 | CN1293975A Chinese patent medicine for treating nephrosis |
| 05/09/2001 | CN1293967A Medicine for treating chronic nephrosis and renal failure and its preparing process |
| 05/09/2001 | CN1065535C Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders |
| 05/08/2001 | US6229002 Complex of nucleic acid which binds to platelet derived growth factor and nonimmunogenic, high molecular weight compound; for targeted diagnostic and therapy; anticarcinogenic agents; cardiovascular disorders; kidney disease |
| 05/08/2001 | US6228858 2,5-methylol-3,6-(aminomethyl)-hydroquinone; diabetes nephropathy; controlling blood sugar |
| 05/08/2001 | US6228834 Treating gramnegative bacterial infections; neutralizing lipopolysaccharides |
| 05/08/2001 | US6228619 Glucosaminidase |
| 05/08/2001 | US6228360 Immunoglobulins binding to human von willebrand factor with chains |
| 05/08/2001 | US6227304 Upper hitch link |
| 05/03/2001 | WO2001031006A2 Serum amyloid a isoform from colostrum |
| 05/03/2001 | WO2001031005A2 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 05/03/2001 | WO2001030978A1 Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| 05/03/2001 | WO2001030844A1 Dna encoding human alpha1g-c t-type calcium channel |
| 05/03/2001 | WO2001030804A2 Salt form of a conjugate useful in the treatment of prostate cancer |
| 05/03/2001 | WO2001030802A2 Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies |
| 05/03/2001 | WO2001030798A1 Transgenic mice containing trp gene disruptions |
| 05/03/2001 | WO2001030788A1 Novel salts of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, their preparation and use |
| 05/03/2001 | WO2001030767A1 Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist |
| 05/03/2001 | WO2001030766A1 Phthalazinone derivatives as pde 4 inhibitors |
| 05/03/2001 | WO2001030763A1 Process for producing optically active naphthalene derivative and optical resolver therefor |
| 05/03/2001 | WO2001030761A1 Heterocyclically substituted benzoylguanidine, method for the production thereof, the use thereof as a medicament or means of diagnosis and a medicament containing the same |
| 05/03/2001 | WO2001030759A2 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 05/03/2001 | WO2001030448A1 Method and compositions for administering taxanes orally to human patients |
| 05/03/2001 | WO2001030376A2 Use of urodilatin for treating chronic kidney failure with residual kidney functions |
| 05/03/2001 | WO2001030353A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 05/03/2001 | WO2001030324A2 Use of acetylsalicylic acid and a preparation for treatment of prostatic hyperplasia |
| 05/03/2001 | WO2001030300A2 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 05/03/2001 | US20010000783 Associated with inhibited epithelial cell proliferation comprising administering a heparin-binding epidermal growth factor-like growth factor (HB-EGF) or derivative, e,g. anantiidiotypic antibody to HB-EGF, gene therapy; angonists |
| 05/03/2001 | DE19951671A1 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist and its use as an endothelin antagonist |
| 05/03/2001 | DE19951471A1 Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen Use of Urodilatin for the treatment of chronic renal insufficiency with residual renal function |
| 05/03/2001 | CA2389583A1 Method and compositions for administering taxanes orally to human patients |
| 05/03/2001 | CA2389031A1 Dna encoding human alpha1g-c t-type calcium channel |
| 05/03/2001 | CA2389020A1 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 05/03/2001 | CA2389012A1 Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist |
| 05/03/2001 | CA2388599A1 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 05/03/2001 | CA2388483A1 Process for producing optically active naphthalene derivative and optical resolver therefor |
| 05/03/2001 | CA2388338A1 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 05/03/2001 | CA2388121A1 Phthalazinone derivatives as pde 4 inhibitors |
| 05/03/2001 | CA2387907A1 Serum amyloid a isoform from colostrum |
| 05/03/2001 | CA2387901A1 Salt form of a conjugate useful in the treatment of prostate cancer |
| 05/03/2001 | CA2387506A1 Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| 05/02/2001 | EP1095044A1 Piperazynil pyrimidine dione compounds selective for adrenoceptors |
| 05/02/2001 | EP1095038A1 Antagonists of gonadotropin releasing hormone |
| 05/02/2001 | EP1095020A1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them |
| 05/02/2001 | EP1095016A1 Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| 05/02/2001 | EP1095015A2 Sulfonylamino carboxylic acid n-arylamides as guanylate cyclase activators |
| 05/02/2001 | EP1094826A1 Novel therapeutic agents that modulate alpha-1a adrenergic receptors |
| 05/02/2001 | EP1094816A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 05/02/2001 | EP1094800A2 PEPTIDYL-PROLYL $i(CIS)-TRANS ISOMERASE INHIBITORS AND USES THEREFOR |
| 05/02/2001 | EP1094798A2 INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE |
| 05/02/2001 | EP1094711A1 Methods for eradication of nanobacteria |
| 05/02/2001 | EP0984959A4 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
| 05/02/2001 | EP0983257A4 Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds |
| 05/02/2001 | EP0973392A4 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds |
| 05/02/2001 | EP0938318B1 Tablet with controlled release of alfuzosine chlorydrate |
| 05/02/2001 | EP0769947B1 Indolinone compounds for the treatment of disease |
| 05/02/2001 | CN1293662A Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
| 05/02/2001 | CN1293655A Bicyclo [2.2.1] heptanes and related compounds |
| 05/02/2001 | CN1293572A Method and means for treating glomerulonephritis |
| 05/02/2001 | CN1065134C Medicine for treatment of stone |
| 05/01/2001 | US6225335 3-(4′-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease |
| 05/01/2001 | US6225331 For therapy and prophylaxis nasal congestion, otitis media, and sinusitis, treating cough, chronic obstructive pulmonary disease (copd) and/or asthma, benign prostatic hypertrophy, cardiovascular disorders, glaucoma, hyperemia, conjunctivitis |
| 05/01/2001 | US6225320 Treatment of pain, inflammation, migraine, emesis and posttherpetic neuralgia |
| 05/01/2001 | US6225308 Tissue selective compounds in the treatment of prostate cancer or benign prostate hypertrophy |
| 05/01/2001 | US6225301 Particularly using the isozyme selective pkc inhibitor, (s)-3,4-(n, n'-1,1'-((2?-ethoxy)-3'?(o)-4'?-(n,n-dimethylamino)-butane)-bi s-(3, 3'-indolyl) )-1(h)-pyrrole-2,5-dione hydrochloride salt |
| 05/01/2001 | US6225085 Nucleotide and amino acid sequence of leucine-rich surface glycoprotein; diagnosis; prophylaxis; therapy; drug screening; fusion proteins; antigenic peptides; antibodies; recombinant production |
| 04/26/2001 | WO2001029206A1 Methods of producing differentiated progenitor cells and lineage-defective embryonic stem cells |
| 04/26/2001 | WO2001029066A2 Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them |
| 04/26/2001 | WO2001029056A1 Tadg-15: an extracellular serine protease overexpressed in carcinomas |